

HEALTHWORLD

22nd Annual Conference

October 2-3, 2023

Athenaeum InterContinental Hotel

Making
Healthcare Reform
a Political and Investment
Priority



ORGANIZER



AMERICAN-HELLENIC
CHAMBER OF COMMERCE

UNDER THE AUSPICES OF



HELLENIC REPUBLIC
Ministry of Health



MedTech Europe
from diagnosis to cure



HEALTHWORLD 2023
CONFERENCE SPONSORS

PLATINUM SPONSORS



AbbVie is a global research-driven biopharmaceutical company. We are committed to developing innovative advanced therapies for some of the world's most complex and serious health issues. AbbVie's mission is to leverage our experience, dedicated people, and unique approach to innovation to significantly improve treatments across five therapeutic areas: Immunology, Hematology, Eye Care, Neuroscience and Aesthetics. More than 47,000 AbbVie employees around the world work daily to develop therapeutic options for patients worldwide.



At **Janssen, the Pharmaceutical Companies of Johnson & Johnson**, we never stop working to create a future where disease is a thing of the past. We tackle society's most pressing health challenges, connecting big ideas to the resources we need to make them a reality. Our goal is to advance access to good health for all. By seeking out medical breakthroughs wherever they occur, leveraging internal expertise and embracing external science, we aim to bring the best solutions to the people who need them.

We focus on areas of medicine where we can make the biggest difference:

- Cardiovascular & Metabolism
- Immunology
- Infectious Diseases & Vaccines
- Neuroscience
- Oncology
- Pulmonary Hypertension

The complex, global healthcare landscape presents new challenges, new diseases and new dynamics. That's why we focus our efforts and resources where the need is high, the science is compelling and where we have the greatest opportunity to save and improve lives. We must work together – across business, academia, governments and society – to lead healthcare's ongoing reinvention. At Janssen, we collaborate with the world for the health of everyone in it.

For Janssen, it is not just about leading innovation and driving medical breakthroughs. We go beyond the medicine by working with patients through the entire process to ensure the best possible experience and health outcomes. We are driven by our belief that “patients are waiting” and there is no time to waste.

For nearly a century, we have fearlessly confronted the world's most devastating and complex diseases. We continue to wage this fight with more strength, determination and expertise than ever before. We are all in until society's most daunting diseases are found only in the pages of history books and good health is in reach for all of humanity.

To learn more, visit our website: www.janssen.com , www.janssen.com/greece/

Follow us at [www.twitter.com/JanssenGlobal](https://twitter.com/JanssenGlobal) , www.linkedin.com/showcase/janssengreece/



At **Johnson & Johnson MedTech**, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible.

For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. We are saving lives and creating a future where healthcare solutions are smarter, less invasive and more personalized.

With a dynamic presence in the Greek market, we responsibly support patients, Healthcare Professionals and society as a whole. We specialize in general surgery (Ethicon), orthopedic surgery (Depuy Synthes), breast reconstruction (Mentor), cardiology and electrophysiology (Biosense Webster), neurovascular care (Cerenovus) and eye health (Johnson & Johnson Vision).

GOLD SPONSORS



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on [Twitter @AstraZeneca](https://twitter.com/AstraZeneca).



BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care.

The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues.

BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.



Bristol Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as Oncology, Cardiovascular, Immunoscience and Fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.

For more information visit our website www.bms-greece.gr

Medtronic plc (www.medtronic.com) based in Dublin, Ireland, is among the world's leading medical technology services and solutions companies - alleviating pain, restoring health and extending the lives of millions of people worldwide. Medtronic employs more than 90K people worldwide, providing services to doctors, hospitals and patients in more than 160 countries.

The company aims to develop partnerships around the world to move healthcare even Further, Together. The main areas in which Medtronic operates are cardiovascular (aortic and peripheral vascular, heart rhythm and coronary heart disease and structural heart disease), diabetes (intensive insulin management, non-invasive diabetes treatments and services), the least invasive treatments (kidney care, respiratory solutions, gastrointestinal and IT sector, surgical innovations), rehabilitation therapies (brain therapies, pain therapies, special therapies, spine treatments), but also other services and solutions (clinical care optimization, functional treatment, patient management, patient management, in value). We have been active in Greece since 1997 with now more than 130 employees in Athens & Thessaloniki.

Today, Medtronic Hellas is a pivotal company in the Greek health care industry and a leader in the transformation of health care delivery through unique innovative therapies and with the focus on new business & services models. Our goal is to create outstanding innovations and to be a partner in healthcare – always with the focus to improve patient care.



MSD

At MSD, known as Merck & Co in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

MSD started operating in Greece in 2010 but some of its products were available through Vianex since 1983. The company provides treatments in oncology, immunology, infectious diseases, diabetes and cardiology and a number of vaccines that protect against 15 diseases out of a total of 18 included in the National Immunization Program. MSD ensures that its activity has a positive impact in the society, implementing actions that contribute to a sustainable Greece and developing partnerships that invest in the country's productivity and development.

MSD in Greece

Since 2010, MSD has been implementing its vision in Greece, to save and improve people's lives, discovering treatments in the fields of oncology, immunology, diabetes and cardiology, committed through its work to benefit patients and to protect public health. At the same time, it ensures that its activity has a positive impact on society, implementing actions that contribute to a sustainable Greece and developing partnerships that invest in the country's productivity and development.

Today, MSD employs over 200 employees providing one of the best working environments in Greece certified as a Great Place to Work. In 2023, it was once again recognized among "The most sustainable companies" in Greece.

More info available at the [new ESG brochure 2022](#) in our site <https://www.msd.gr> and in our Social Media channels, LinkedIn, Facebook, Twitter και YouTube.



About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics.

The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

SILVER SPONSORS



Alcon is the global leader in eye care, with complementary businesses in Surgical and Vision Care, dedicated to helping people see brilliantly. Our over 75-year history of success rests on a foundation of industry expertise, leading brands and winning mindset.

We aspire to improve lives, strengthen communities and create long-term value by innovating products that improve sight. Our dedicated and energized workforce is committed to serving customers, expanding access and fulfilling our mission to help people around the world see brilliantly.

We are an innovation leader with 1600 dedicated Research & Development (R&D) associates, more than 100 projects in our development pipeline, and one of the largest R&D commitments in the market. In 2022, we invested over \$702 million in R&D.

Alcon is the global leader in Surgical eye care, delivering better patient outcomes and customer experiences. We are committed to serving the evolving needs of eye surgeons with our equipment ecosystem, which includes our best in class equipment platforms for cataract, refractive and vitreoretinal surgery and the leading IOLs. In order to increase customer experience we offer surgeons world class training, education and service with global scale and reach.

Alcon has a leading position in Vision Care, helping address the growing consumer need for improved vision, comfort, ocular health and convenience, with a differentiated portfolio of leading brands. Ocular health comprises our dry eye business and contact lens care.

Alcon aspires to lead a world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.



About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Boston Scientific is a global medical technology leader for over 40 years having 45,000 employees. Our company is dedicated to **transforming lives** through **innovative medical solutions** that **improve the health** of patients around the world. We work with a broad range of medical specialists including interventional cardiologists and radiologists, electrophysiologists, gastroenterologists, oncologists, gynecologists and urologists. We help physicians treat about 33 million patients each year using a wide range of more than 16,000 products. Our commitment to innovation drives us to invest approximately 1,3 billion usd annually on research and development. Our culture and values are what differentiate Boston Scientific from other companies:

- **Caring**: with integrity
- **Meaningful Innovation**
- **High Performance**: to benefit patients, clinicians and shareholders
- **Global Collaboration**
- **Diversity**: we embrace the value of the unique talents, ideas and experiences of our employees
- **Winning Spirit**: agility and accountability to further improve patient care

For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.



**Building a better
working world**

EY exists to build a better working world, helping create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate. Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY has been operating in Greece since 1926. EY in Greece has offices in Athens, Thessaloniki and Patras. It is part of the EMEIA (Europe, Middle East, India, Africa) region and one of the 31 countries that comprise the CESA (Central, Eastern and Southeastern Europe & Central Asia) region; the largest and most culturally diverse region of EY.

To learn more about EY, please visit ey.com/el_gr



Who we are

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway.

Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an \$18 billion business with 51,000 employees working to create a world where healthcare has no limits.

Our key metrics

1B+	\$18B
Patients served annually	Revenue
18.5K	\$1B
Customer-facing employees	Annual R&D and product investment spend
4M+	42
Installed base equipment	AI-enabled device authorizations in US

Our leadership positions

Imaging: Scanning devices, clinical applications, service capabilities, and digital solutions

- Large, global installed base with growing fleet enterprise solutions, data integration, & digital sales
- NPI pipeline focused on innovation breakthroughs and growth industries

Patient Care Solutions: Medical devices, services, consumable products, and digital solutions

- Decades of clinical innovation and trusted solutions, with global monitoring solutions portfolio
- Growing digital solutions with clinical decision support

Ultrasound: Screening, diagnosis, therapy guidance, and monitoring of multiple diseases

- Defining the category for over 25 years, with a large global installed base
- Care pathways, AI and digital innovation driving future growth

Pharmaceutical Diagnostics: Diagnostic imaging agents to enhance radiology and nuclear medicine procedures across care pathways

- Industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging
- Driving innovation through funnel of new products and improving customer productivity
- Foundation of global commercial reach and a vertically integrated supply chain

About GE HealthCare

- We execute on our precision care strategy, at the forefront of care delivery across the patient journey
- We play a central role in healthcare digitization with 200+ software apps driving breakthroughs in clinical insights
- We are an industry-defining innovator with 9,700 engineers and scientists focused on R&D
- We are a leader in an attractive \$84B global healthcare market
- We are led by an experienced leadership team with the right strategic vision:

Peter J. Ard
President and
Executive Officer

Helmut Zödl
VP &
Chief Financial Officer



GENESIS Pharma: The Greek pharmaceutical company that invests in global innovation for more than two decades

The leading Greek pharmaceutical company GENESIS Pharma was founded with the mission to address unmet patient needs through innovation. It was one of the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative medicines.

Through long-standing strategic partnerships with some of the leading global pharmaceutical companies committed to cutting-edge R&D, GENESIS Pharma has created a strong portfolio of innovative and high therapeutic value pharmaceutical products for more than 30 severe and rare diseases.

With extensive expertise in the field of hematology-oncology, the company represents innovative medicines for rare types of leukemia and lymphomas, as well as oncology medicines for breast and ovarian cancer, osteosarcoma and cholangiocarcinoma.

It is acknowledged as one of the most specialized companies in multiple sclerosis in Greece with an extensive product portfolio for the disease and an expertise of more than 20 years, as it exclusively represents Biogen, a leading company in multiple sclerosis and neuroscience research worldwide.

Its portfolio also includes pioneering treatments for rare genetic diseases. Amongst these, the first therapy approved for the treatment of spinal muscular atrophy (SMA), the first oral treatment coming from research in precision medicine for Fabry disease, as well as 3 first-in-class siRNA therapeutics, based on Nobel Prize-winning science, for hATTR amyloidosis, primary hyperoxaluria and acute hepatic porphyria.

The company's extended product portfolio is complemented by branded pharmaceuticals in the fields of dermatology, hepatology, nephrology and cardiology, an intravenous iron replacement product, as well as biosimilar products of advanced biologics for a range of rheumatological, dermatological and gastrointestinal chronic inflammatory diseases.

GENESIS Pharma is one of the most awarded companies in the country for its commitment to sustainable development and good working environment, with a yearly contribution to the Greek economy and society that exceeds 30% of its annual turnover.



GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.

We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

We deliver more than 50 innovative medicines for diseases such as diseases of the respiratory system (chronic obstructive pulmonary disease and asthma), HIV/AIDS, rare diseases and oncology. In parallel, as a leader in vaccine development, we provide vaccines for the prevention of the total diseases which are described in the National Vaccination Programme for children and adolescents.

We contribute to the Greek economy, and we employ 150 people. We take initiatives that assist the activities of the state and the National Healthcare System, in addition to improving patients' living and supporting the actions of their healthcare professionals.

We closely collaborate with the healthcare professionals who provide us with scientific and medical insights as well as specialised advice on patients' care, while due to our commitment to corporate social responsibility, we support vulnerable social groups and collaborate with patient advocacy groups, supporting their actions. Our values and expectations are at the core of our activities, enabling us to deliver our ambition and purpose to unite science, technology and talent to get ahead of disease together.



As a result of the merger of **IMS Health**, a world leader in data analysis & technology solutions exclusively in the field of Health, and **Quintiles**, one of the world's leading companies in Clinical Studies, **IQVIA**, based in the USA, has a presence in **100+ countries with 90K employees**.

In **Greece**, we have been active since 1968, counting now **almost 370 employees** and collaborating with all Healthcare professionals as well as Hospitals. In numerical terms, IQVIA Hellas has a network of 3.5K doctors and 3K pharmacies for data collection & primary research studies, while conducting at least 120 clinical studies at over 100 sites. We also **work closely with all partners in Healthcare ecosystem**, such as institutions, authorities, collective bodies of health scientists and pharmaceutical companies, as well as patient associations, providing our services to **over 150 clients**.

Ακολουθείστε την IQVIA στα **social media**: / Follow IQVIA in **social media** to learn more:



<https://www.iqvia.com/locations/greece>



<https://www.linkedin.com/company/iqvia>



https://twitter.com/IQVIA_global



<https://www.facebook.com/IQVIA/>

Press contact

Evgenia Trimmi, Business Development & Offering Associate Director, evgenia.trimmi@iqvia.com



KALTEQ SA is a Greek medical company, with 20-years of presence in the Greek & Cypriot Market and through its stable and continuous development, is now one of the fastest growing Companies, in the field of Medical Technology products in the Health Sector.

The combination of providing excellent quality products, consistency, immediate response, well-trained staff and constant presence to its customers, are the main characteristics of its successful course, until today. Driven by its commitment to provide top quality products for the benefit of patients and healthcare providers, KALTEQ is dedicated to building strong partnerships, with the Vision to improve the quality of people's lives and the Goal to build a better future in Healthcare.

KALTEQ currently employs 130 persons and is constantly creating new job opportunities. The Company invests in new Exclusive collaborations & synergies with Leading Internationally recognized Manufacturers and has Branches in Thessaloniki, Heraklion, Patras and Nicosia.

At the same time, through partnerships with sub-distributors, the Company is developing its presence in ten countries of the South-Eastern Europe and Balkans. KALTEQ offers products, technologies and services that cover a wide range of surgical and interventional specialties and Hospitals' needs, in the fields of General Surgery, Laparoscopic Surgery, Cardiac Surgery, Neurosurgery, Neuronavigation, Chronic Pain, ENT, Sanitary Equipment, Sterilization Systems, etc. (www.kalteq.com)

Over the years, through collaborations with innovative manufacturers, KALTEQ has been established as a leading company in the hospital sector in Greece and is a strong partner that provides integrated solutions, with consistency and professionalism.

At the same time, it has been distinguished within the last 5 years as a Company with a very important footprint in the Greek Economy and goals for continuous medium-term investments in the next 5 years (Diamonds of the Greek Economy, Protagonists of the Greek Economy, Healthcare Business Award, etc.)

In addition, it owns quality certifications by internationally recognized Organizations such as TUV, Trace, Epic, etc.

With a keen eye to the Future, KALTEQ will continue its upward trajectory, contribute and promote in the best possible way the development of the Healthcare field and will attend closely the needs of patients and Healthcare Providers, with consistency to its Goals and Vision.



It all begins with a Promise
To make people's lives better

About Pharmaserve-Lilly:

Pharmaserve was founded in Athens in 1984. Pharmaserve-Lilly was formed in 1994, a joint venture between the Greek pharmaceutical company Pharmaserve and the American multinational pharmaceutical company Lilly.

Today, Pharmaserve-Lilly, is among the top ten pharmaceutical companies in Greece.

Being an innovative company in the health care sector, Pharmaserve-Lilly invests in its expertise and experience to implement research & development programs of innovative products in cooperation with Lilly around the world and from collaborations with eminent scientific organizations.

The therapeutic areas we provide solutions:

- Diabetes
- Oncology
- Dermatology
- Rheumatology
- Musculoskeletal Diseases
- Central Nervous System
- Pain
- Urology
- Cardiology
- Developmental disorders

Clinical Research in our Company:

The Medical Department of Pharmaserve-Lilly since its establishment in 1996, is firmly committed to the vision of excellency in the conduct of Clinical Research Programs.

Today, our research department has been recognized on a national and international level for its important scientific activity.

Follow us



For further information visit our website www.lilly.gr

The Sanofi logo consists of the word "sanofi" in a bold, lowercase, sans-serif font. The letter 's' is black, while the letters 'a', 'n', 'o', and 'i' are black with a small purple dot above each of them.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives.

Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.